TSHA Taysha Gene Therapies, Inc.
Q3 2025 10-Q
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Taysha Gene Therapies, Inc. (TSHA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New legal risk: SEC subpoenas in late 2024 investigating August 2023 PIPE and public offerings
- • Materially updated clinical risk: May 2025 Phase 1/2 REVEAL TSHA-102 data preliminary, may materially change as more patient data accrue
Get deeper insights on Taysha Gene Therapies, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.